Inmagene Biopharmaceuticals is a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory diseases. The company's lead asset includes IMG-007, a nondepleting anti-OX40 monoclonal antibody. Inmagene Biopharmaceuticals, formerly known as Ikena Oncology Inc., is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $0.80M |
| Net Income (Most Recent Fiscal Year) | $-45.35M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.48 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -5712.38% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -38.96% |
| Return on Assets (Trailing 12 Months) | -34.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 18.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 18.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.57 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.95 |
| Earnings per Share (Most Recent Fiscal Year) | $-9.64 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 10.65M |
| Free Float | 10.02M |
| Market Capitalization | $58.81M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 0.73 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.94% |
| Percentage Held By Institutions (Latest 13F Reports) | 75.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |